Morgan Stanley raised the firm’s price target on CVS Health (CVS) to $93 from $89 and keeps an Overweight rating on the shares. Guidance for a mid-teens 2026-28 EPS compound annual growth rate was “well received” and “nicely ahead” of the prior 6% floor, while 2026 guidance was issued in-line with prior commentary with added detail, the analyst says following the company’s investor day. The event leaves the firm with increased conviction in the earnings power and trajectory of the business, the analyst added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- CVS Health price target raised to $93 from $87 at Barclays
- CVS Health price target raised to $97 from $96 at UBS
- CVS Health: Strong Financial Outlook and Strategic Initiatives Drive Buy Rating
- CVS Health’s Promising Growth Trajectory and Strategic Focus Drive Buy Rating
- CVS Health: Strategic Initiatives and Financial Outlook Drive Buy Rating